The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated. METHODS: In a cohort study, we included 271,174 patients with type 2 diabetes who were registered in the Swedish National Diabetes Register and matched them with 1,355,870 controls on the basis of age, sex, and county. We assessed patients with diabetes according to age categories and according to the presence of five risk factors (elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, albuminuria, smoking, and elevated blood pressure). Cox regression was used to study the excess risk of outcomes (death, acute myocardial infarction, stroke, and hospitalization for heart failure) associated with smoking and the number of variables outside target ranges. We also examined the relationship between various risk factors and cardiovascular outcomes. RESULTS: The median follow-up among all the study participants was 5.7 years, during which 175,345 deaths occurred. Among patients with type 2 diabetes, the excess risk of outcomes decreased stepwise for each risk-factor variable within the target range. Among patients with diabetes who had all five variables within target ranges, the hazard ratio for death from any cause, as compared with controls, was 1.06 (95% confidence interval [CI], 1.00 to 1.12), the hazard ratio for acute myocardial infarction was 0.84 (95% CI, 0.75 to 0.93), and the hazard ratio for stroke was 0.95 (95% CI, 0.84 to 1.07). The risk of hospitalization for heart failure was consistently higher among patients with diabetes than among controls (hazard ratio, 1.45; 95% CI, 1.34 to 1.57). In patients with type 2 diabetes, a glycated hemoglobin level outside the target range was the strongest predictor of stroke and acute myocardial infarction; smoking was the strongest predictor of death. CONCLUSIONS: Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“when all major cardiovascular risk factors are treated to within the target ranges, people with type 2 diabetes have risk of death, MI, or stroke similar to that of the general population (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among persons with type 2 diabetes (T2D), cardiovascular risk and mortality are dependent on the number of uncontrolled risk factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the evidence from prospective intervention studies to support comprehensive ASCVD risk factor reduction, a large cohort study confirmed no or only marginally increased mortality, MI, and stroke risk compared with the general population when all major cardiovascular risk factors are managed to goal levels in people with type 2 diabetes (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hypertriglyceridemia is indirectly linked with changes in HDL-C and LDL-C composition that are conducive to accelerated atherogenesis.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In persons with fasting triglycerides of 200 to 499 mg/dL, despite tight adherence to a healthy diet (to include reduced intake of simple carbohydrates and avoidance of fruit juices and alcohol) and optimized glycemia control, prescribe statin therapy to the maximum tolerated dose to achieve goals for non-HDL-C or apo B, since all apo B–containing particles are potentially atherogenic.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To date, aside from icosapent ethyl, fish oil therapy has not been shown to prevent CV adverse events.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“No RCT has yet been reported to investigate the benefit of reducing severe (>500 mg/dL) or moderate (>200 mg/dL) hypertriglyceridemia to prevent CVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite these newer therapies, the risk of kidney failure remains high, particularly in those whose risk factors are insufficiently controlled.6,7”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with advanced disease, e.g.T2DM and established microalbuminuria, an intensive, target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%, total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) resulted in 50% fewer microvascular and macrovascular events after 7.8 years of follow-up.361”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [361]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 999
Sano, M. (2020) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944720939383 · Cited by 24
Qie, R., Chen, Q., Wang, T., Chen, X., Wang, J., Cheng, R., Lin, J., Zhao, Y., Liu, D., Qin, P., et al. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-00848-z · Cited by 24
Control of Cardiovascular Risk Factors in Patients with Chronic Obstructive Pulmonary Disease
Hawkins, N. M., Peterson, S., Ezzat, A. M., Vijh, R., Virani, S., Gibb, A. G., Mancini, G. B. J., & Wong, S. T. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202104-463oc · Cited by 24
Smoking and Diabetes: Sex and Gender Aspects and Their Effect on Vascular Diseases
Tramunt, B., Rouland, A., Durlach, V., Vergès, B. L., Thomas, D., Berlin, I., & Clair, C. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.01.018 · Cited by 26
Liang, Y. Y., He, Y., Wang, J., Liu, Y., Ai, S., Feng, H., Zhu, C., Li, H., Zhou, Y., Zhang, J., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.05.004 · Cited by 26
Approaches to risk assessment among older patients with diabetes
Pilla, S. J., Schoenborn, N. L., Maruthur, N. M., & Huang, E. S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1172-z · Cited by 24
BH4 Increases nNOS Activity and Preserves Left Ventricular Function in Diabetes
Carnicer, R., Duglan, D., Žiberna, K., Récalde, A., Reilly, S. N., Simon, J. N., Mafrici, S. F., Arya, R., Roselló‐Lletí, E., Chuaiphichai, S., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.316656 · Cited by 23
Augestad, I. L., Dekens, D., Karampatsi, D., Elabi, O., Zabala, A., Pintana, H., Larsson, M., Nyström, T., Paul, G., Darsalia, V., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15524 · Cited by 21
Giugliano, D., Ceriello, A., De Nicola, L., Perrone‐Filardi, P., Cosentino, F., & Esposito, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13881 · Cited by 22
Hashemi Madani, N., Ismail-Beigi, F., Poustchi, H., Nalini, M., Sepanlou, S. G., Malek, M., Abbasi, M. A., Khajavi, A., Khamseh, M. E., & Malekzadeh, R. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01390-8 · Cited by 22
Risk of Ischemic and Hemorrhagic Stroke in Individuals With Type 1 and Type 2 Diabetes
Mavridis, A., Viktorisson, A., Eliasson, B., von Euler, M., & Sunnerhagen, K. S. (2025) · Neurology · doi:10.1212/wnl.0000000000213480 · Cited by 26
Self-citationHan, B. G., Lee, J. Y., Kim, M. R., Shin, H., Kim, J. S., Yang, J. W., & Kim, J. Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235640 · Cited by 24
Control of Adipose Cell Browning and Its Therapeutic Potential
Lizcano, F., & Arroyave, F. (2020) · Metabolites · doi:10.3390/metabo10110471 · Cited by 23
Kwon, H., Moon, Y., Kim, K., Shin, W., Huh, I., Jun, I., Song, J., & Hwang, G. (2020) · Hepatology · doi:10.1002/hep.31661 · Cited by 23
Chun, H. S., Lee, J. S., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Lee, Y., Kim, Y. D., & Kim, S. U. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15387 · Cited by 23
Changes in the Diagnosis and Management of Diabetes in Mexico City Between 1998–2004 and 2015–2019
Aguilar-Ramirez, D. J., Alegre-Díaz, J., Gnatiuc, L., Ramírez-Reyes, R., Wade, R. L., Hill, M., Collins, R., Peto, R., Emberson, J., Herrington, W. G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2276 · Cited by 23
Wang, L., Cong, H., Zhang, J., Hu, Y., Wei, A., Zhang, Y., Yang, H., Ren, L., Qi, W., & Li, W. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.718604 · Cited by 23
Salinero-Fort, M. Á., Andrés-Rebollo, F. J. S., Cárdenas‐Valladolid, J., Méndez‐Bailón, M., Chico-Moraleja, R. M., Pau, E. C. D. S., Jiménez‐Trujillo, I., Gómez-Campelo, I., de Burgos‐Lunar, C., de Miguel-Yanes, J. M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94121-8 · Cited by 24
dos Reis, R. C. P., Duncan, B. B., Szwarcwald, C. L., Malta, D. C., & Schmidt, M. I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153428 · Cited by 24
Gerbaud, É., de la Poterie, A. B., Baudinet, T., Montaudon, M., Beauvieux, M.-C., Lemaître, A.-I., Cetran, L., Séguy, B., Picard, F., Vélayoudom, F.-L., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061549 · Cited by 24
Ananth, C. V., Rutherford, C. G., Rosenfeld, E. B., Brandt, J. S., Graham, H. L., Kostis, W. J., & Keyes, K. M. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.05.006 · Cited by 23
Darsalia, V., Johansen, O. E., Lietzau, G., Nyström, T., Klein, T., & Patrone, C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00493 · Cited by 23
Lee, J., Moon, J. S., Kang, D. R., Lee, S. J., Son, J., Youn, Y. J., Ahn, S. G., Ahn, M., Kim, J., Yoo, B., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020505 · Cited by 23
Chen, Y., Lin, H., Qin, L., Lu, Y., Zhao, L., Xia, M., Jiang, J., Li, X., Yu, C., Zong, G., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2494 · Cited by 23
Ferrannini, G., Norhammar, A., Gyberg, V., Mellbin, L., & Rydén, L. (2020) · Diabetes Care · doi:10.2337/dci20-0002 · Cited by 23
Wargny, M., Croyal, M., Ragot, S., Gand, E., Jacobi, D., Trochu, J.-N., Prieur, X., Le May, C., Goronflot, T., Cariou, B., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01505-9 · Cited by 21
Digital Health in Diabetes and Cardiovascular Disease
Avoke, D., Elshafeey, A., Weinstein, R. A., Kim, C. H., & Martin, S. S. (2024) · Endocrine Research · doi:10.1080/07435800.2024.2341146 · Cited by 24
Rouland, A., Thuillier, P., Al‐Salameh, A., Benzerouk, F., Bahougne, T., Tramunt, B., Berlin, I., Clair, C., Thomas, D., Faou, A.-L. L., et al. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.08.001 · Cited by 27
Nalini, M., Khoshnia, M., Kamangar, F., Sharafkhah, M., Poustchi, H., Pourshams, A., Roshandel, G., Gharavi, S., Zahedi, M., Norouzi, A., et al. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa126 · Cited by 22
Trajectories in HbA1c and other risk factors among adults with type 1 diabetes by age at onset
Edqvist, J., Rawshani, A., Rawshani, A., Adiels, M., Franzén, S., Bjorck, L. M., Svensson, J., Lind, M., Sattar, N. A., & Rosengren, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002187 · Cited by 25
Self-citationZhang, Y., Liu, C., Xu, Y., Wang, Y., Dai, F., Hu, H., Tian, J., Lu, Y., & Zhang, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1036146 · Cited by 22
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01773-z · Cited by 25
Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus
Greene, S. J., & Butler, J. (2019) · Circulation · doi:10.1161/circulationaha.118.037599 · Cited by 22
Predictors of heart failure development in type 2 diabetes
Verma, S., Sharma, A., Kanumilli, N., & Butler, J. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000647 · Cited by 22
Zaccardi, F., Davies, M. J., & Khunti, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13929 · Cited by 22
Wu, T., Hsu, F., & Pierce, J. P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061817 · Cited by 22
Iwase, M., Komorita, Y., Ohkuma, T., Fujii, H., Ide, H., Yoshinari, M., Oku, Y., Higashi, T., Nakamura, U., & Kitazono, T. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108518 · Cited by 22
Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
Zeng, Q., Zhou, Q., Liu, W., Wang, Y., Xu, X., & Xu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.636152 · Cited by 23
Genetically determined tobacco and alcohol use and risk of atrial fibrillation
Lu, Y., Guo, Y. P., Lin, H., Wang, Z., & Zheng, L. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00915-0 · Cited by 23
Hellgren, M. I., Svensson, A., Franzén, S., Ericsson, Å., Guðbjörnsdóttir, S., Ekström, N., Bertilsson, R., Valentine, W. J., & Malkin, S. J. P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14376 · Cited by 21
Self-citationXiao, X., Zhang, J., Lang, Y., Cai, L., Yang, Q., Liu, K., Ji, S., Ju, X., & Liu, F. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110838 · Cited by 23
Emerging uncertainty on the anti-aging potential of metformin
Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102817 · Cited by 24
Jabin, A., & Guthrie, A. (2025) · International Journal of Social and Psychological Aspects of Healthcare · doi:10.51847/k4r85uzgeq · Cited by 21
Rauchen, Alkohol und Diabetes mellitus (Update 2019)
Brath, H., Kaser, S., Tatschl, C., & Fasching, P. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1455-z · Cited by 21
The Weakness of the Strong Sex: Differences Between Men and Women Affected by Diabetic Foot Disease
Iacopi, E., Pieruzzi, L., Riitano, N., Abbruzzese, L., Goretti, C., & Piaggesi, A. (2021) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734620984604 · Cited by 21
Vági, O. E., Svébis, M. M., Domján, B. A., Körei, A. E., Istenes, I., Putz, Z., Mészáros, S., Hajdú, N., Békeffy, M. Z., Tesfaye, S. H., et al. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6662159 · Cited by 24
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 24
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 25
Lăcătușu, C.-M., Grigorescu, E.-D., Stătescu, C., Sascău, R. A., Onofriescu, A., & Mihai, B. M. (2019) · Medicina · doi:10.3390/medicina55090592 · Cited by 23
Ferrini, M., Johansson, I., & Aboyans, V. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885461 · Cited by 21
Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population
Schmitt, V. H., Billaudelle, A.-M., Schulz, A., Keller, K., Hahad, O., Tröbs, S., Koeck, T., Michal, M., Schuster, A. K.-G., Toenges, G., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173851 · Cited by 21
Heerspink, H. J. L., Lu, Z., Du, Y., Duffin, K. L., Coskun, T., Haupt, A., & Hartman, M. L. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.03.049 · Cited by 23
Kabisch, S., Meyer, N. M. T., Honsek, C., Gerbracht, C., Dambeck, U., Kemper, M., Osterhoff, M. A., Birkenfeld, A. L., Arafat, A. M., Weickert, M. O., et al. (2019) · Nutrients · doi:10.3390/nu11112726 · Cited by 20
Ji, X., Dong, X., Li, J., Tai, G., Qiu, S., Wei, W., Silumbwe, C. W., Damdinjav, D., Otieno, J. N., Li, X., et al. (2025) · Phytotherapy Research · doi:10.1002/ptr.8507 · Cited by 23
Patsoukaki, V., Lind, L., Lampa, E., Radhi, S. H., Eeg‐Olofsson, K., Eliasson, B., & Eriksson, J. W. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00165-2 · Cited by 24
Self-citationLiu, J., Pong, A., Gallo, S., Darekar, A., & Terra, S. G. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0856-7 · Cited by 21
Challenging 2019 ESC guidelines for the management of type 2 diabetes
Scheen, A. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.10.006 · Cited by 20
Funamizu, T., Iwata, H., Nishida, Y., Miyosawa, K., Doi, S., Chikata, Y., Shitara, J., Endo, H., Wada, H., Naito, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-00996-8 · Cited by 23
Influence of aging on deterioration of patients with COVID-19
Pang, L., Liu, Y., Shen, M., Ye, J., Chen, R., Lan, Z., Wu, Z., Guo, Y., & Zhang, P. (2020) · Aging · doi:10.18632/aging.202136 · Cited by 20
Maranta, F., Cianfanelli, L., Rizzo, M., & Cianflone, D. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.12.074 · Cited by 20
Elrashidy, R. A., & Ibrahim, S. E. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115533 · Cited by 20
Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus
Román, G., & Stoian, A. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97422 · Cited by 26
Carlsson, S., Andersson, T., Talbäck, M., & Feychting, M. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01320-8 · Cited by 20
Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis
Liu, L., Shi, F., Xu, H., Wu, Y., Gu, Z., & Lin, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752440 · Cited by 20
Gyldenkerne, C., Kahlert, J. A., Olesen, K. K. W., Thrane, P. G., Sørensen, H. T., Thomsen, R. W., & Mæng, M. (2022) · Diabetes Care · doi:10.2337/dc22-0440 · Cited by 21
Predictive models of diabetes complications: protocol for a scoping review
Ndjaboué, R., Farhat, I., Ferlatte, C.-A., Ngueta, G., Guay, D., Delorme, S., Ivers, N. M., Shah, B. R., Straus, S. E., Yu, C. H. Y., et al. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01391-w · Cited by 20
Economic and clinical burden of comorbidities among patients with acromegaly
Whittington, M. D., Muñoz, K. A., Whalen, J. D., Ribeiro‐Oliveira, A., & Campbell, J. D. (2021) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2021.101389 · Cited by 20
Horwitz, D., Padron, C. K., Kelly, T., Saunders, J. K., Ude‐Welcome, A., Schmidt, A., & Parikh, M. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2020.01.016 · Cited by 19
TEMD Study Group, Bayram, F., Sönmez, A., Haymana, C., Sabuncu, T., Dizdar, O. S., Gürkan, E., Çarlıoğlu, A., Ağbaht, K., Özdemir, D., et al. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01408-2 · Cited by 22
Association Between Physical Activity and Mortality Among Community-Dwelling Stroke Survivors
Joundi, R. A., Patten, S. B., Lukmanji, A., Williams, J. V. A., & Smith, E. E. (2021) · Neurology · doi:10.1212/wnl.0000000000012535 · Cited by 19
Ma, I., Genet, T., Clémenty, N., Bisson, A., Herbert, J., Semaan, C., Bouteau, J., Angoulvant, D., Ivanés, F., & Fauchier, L. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab073 · Cited by 19
Whyte, M., Joy, M., Hinton, W., McGovern, A. P., Hoang, U., van Vlymen, J. N., Ferreira, F. M., Mount, J., Munro, N. M., & de Lusignan, S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14705 · Cited by 17
Vora, J. P., Cherney, D. Z. I., Kosiborod, M., Spaak, J., Kanumilli, N., Khunti, K., Lam, C. S. P., Bachmann, M., Fenici, P., & the CaReMe Global Alliance (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15485 · Cited by 26
The quality of care in type 1 and type 2 diabetes – A 2023 update of the AMD Annals initiative
Russo, G. T., Cosmo, S. D., Bartolo, P. D., Lucisano, G., Manicardi, V., Nicolucci, A., Rocca, A., Rossi, M. C., Cianni, G. D., & Candido, R. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111743 · Cited by 19
Zhang, F., Xie, Y., Ma, X., Gu, L., Li, H., Li, X., Guo, G., & Zhang, X. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.11.010 · Cited by 18
Gunn, L. H., Vamos, E. P., Majeed, A., Normahani, P., Jaffer, U., Molina, G., Valabhji, J., & McKay, A. J. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002069 · Cited by 19
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 19
Gurung, R. L., Yiamunaa, M., Liu, S., Liu, J., Chan, C., Choo, R. W. M., Ang, K., Sum, C. F., Subramaniam, T., & Lim, S. C. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0867-4 · Cited by 19
Butler, J., Anker, S. D., Filippatos, G., Usman, M. S., Ferreira, J. P., Zannad, F., & Packer, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab704 · Cited by 18
Igarashi, A., Maruyama-Sakurai, K., Kubota, A., Akiyama, H., Yajima, T., Kohsaka, S., & Miyata, H. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01270-8 · Cited by 17
Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes
Elías-López, D., Wadström, B. N., Vedel‐Krogh, S., Kobylecki, C. J., & Nordestgaard, B. G. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01555-1 · Cited by 18
Heparan Sulfate Proteoglycans in Diabetes
Hiebert, L. M. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1724118 · Cited by 16
Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice
Davis, C. M., Zhang, W. H., Allen, E. M., Bah, T. M., Shangraw, R. E., & Alkayed, N. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115419 · Cited by 17
Cai, C., Liu, Y., Li, Y., Shi, Y., Zou, H., Bao, Y., Shen, Y., Cui, X., Fu, C., Jia, W., et al. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0897-7 · Cited by 19
Carrera, M. J., Moliner, P., Llauradó, G., Enjuanes, C., Conangla, L., Chillarón, J. J., Ballesta, S., Climent, E., Colet, J. C., & Roux, J. A. F. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010006 · Cited by 19
Age at diagnosis of type 2 diabetes and cardiovascular risk factor profile: A pooled analysis
Barker, M. M., Zaccardi, F., Brady, E. M., Gulsin, G. S., Hall, A. P., Henson, J. J., Htike, Z. Z., Khunti, K., McCann, G. P., Baldry, E. L., et al. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i3.260 · Cited by 18
Hepatitis C virus infection and diabetes: A complex bidirectional relationship
Ciardullo, S., Mantovani, A., Ciaccio, A., Carbone, M., Invernizzi, P., & Perseghin, G. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109870 · Cited by 21
The impact of heat therapy on neuromuscular function and muscle atrophy in diabetic rats
AlSabagh, A. T., Rao, M. S. R., & Renno, W. M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2022.1039588 · Cited by 22
Bell, D. S. H., McGill, J. B., & Jerkins, T. W. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15181 · Cited by 18
Dijk, W., & Cariou, B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13636 · Cited by 19
Bragança, B., & Correia‐de‐Sá, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145005 · Cited by 18
Lee, S., Han, K., Kim, H., Cho, J., Yoon, K., & Kim, M. K. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.704 · Cited by 17
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.07.003 · Cited by 19
McKay, A. J., Gunn, L. H., Sathish, T., Vamos, E. P., Nugawela, M. D., Majeed, A., Molina, G., & Sivaprasad, S. (2021) · BMC Medicine · doi:10.1186/s12916-021-01966-x · Cited by 19
Lee, K. S., Russ, B. P., Wong, T. Y., Horspool, A. M., Winters, M. T., Barbier, M., Bevere, J. R., Martínez, I., Damron, F. H., & Cyphert, H. A. (2022) · iScience · doi:10.1016/j.isci.2022.105038 · Cited by 18
Edqvist, J., Rawshani, A., Adiels, M., Bjorck, L. M., Lind, M., Svensson, A., Gudbjörnsdottir, S., Sattar, N. A., & Rosengren, A. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013871 · Cited by 16
Self-citationKalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
Fu, Y., Lu, M., Zhang, K., Sun, Y. B., Tan, X. W., Wang, N., Xu, F., Jiang, B., Lu, Y., & Wang, B. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae221 · Cited by 18
Ostrominski, J. W., Harrington, J., Claggett, B. L., Filippatos, G. S., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., Shah, S. J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.039 · Cited by 17
Bee venom ameliorates cardiac dysfunction in diabetic hyperlipidemic rats
Zahran, F. M., Mohamad, A. S., & Zein, N. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211045924 · Cited by 17
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- Uppsala University (SE)
- From the Department of Molecular and Clinical Medicine, Institute of Medicine (Aidin Rawshani, Araz Rawshani, B.E., A. Rosengren, S.G.), and the Health Metrics Unit, Sahlgrenska Academy (S.F.), University of Gothenburg, and the Swedish National Diabetes Register, Center of Registers in Region (Aidin Rawshani, Araz Rawshani, S.F., B.E., A.-M.S., M.M., S.G.), Gothenburg, and the Department of Public Health and Caring Sciences–Geriatrics, Uppsala University, and the Swedish Medical Products Agency,...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-16
- Volume
- 379
- Issue
- 7
- Pages
- 633-644
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2887185538
- Cited by
- 1,475
- References
- 22
- Citations by year
- 2026: 158 · 2025: 172 · 2024: 178 · 2023: 175 · 2022: 197 · 2021: 219 · 2020: 210 · 2019: 141 · 2018: 20
- FWCI
- 116.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular risk factors, mortality, acute myocardial infarction, stroke, heart failure hospitalization, HbA1c, LDL cholesterol, albuminuria, smoking, blood pressure, Swedish National Diabetes Register, matched cohort comparison
- MeSH terms
- Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypercholesterolemia, Hypertension, Male, Middle Aged, Myocardial Infarction, Risk Factors, Smoking, Sweden, Cohort Studies, Body Mass Index, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
